Want to see BNTX full AI Analyst Report?

BioNTech SE (BNTX) Stock Forecast & Price Target

4,851 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

BNTX Analyst Ratings

Strong Buy

10 Buy

2 Hold

0 Sell

Based on 12 analysts giving stock ratings to

BioNTech

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

BNTX Stock 12 Month Forecast

Average Price Target

$124.58

▲(39.46% Upside)

Based on 12 Wall Street analysts offering 12 month price targets for BioNTech SE in the last 3 months. The average price target is $124.58 with a high forecast of $142.00 and a low forecast of $92.00. The average price target represents a 39.46% change from the last price of $89.33.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"88":"$88","143":"$143","101.75":"$101.8","115.5":"$115.5","129.25":"$129.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":142,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$142.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":124.58333333333333,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$124.58</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":92,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$92.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[88,101.75,115.5,129.25,143],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,90.58,94.53538461538461,98.49076923076923,102.44615384615385,106.40153846153846,110.35692307692308,114.31230769230768,118.2676923076923,122.22307692307692,126.17846153846153,130.13384615384615,134.08923076923077,138.04461538461538,{"y":142,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,90.58,93.19564102564102,95.81128205128205,98.42692307692307,101.0425641025641,103.65820512820513,106.27384615384615,108.88948717948718,111.5051282051282,114.12076923076923,116.73641025641025,119.35205128205128,121.9676923076923,{"y":124.58333333333333,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,90.58,90.68923076923076,90.79846153846154,90.9076923076923,91.01692307692308,91.12615384615384,91.23538461538462,91.34461538461538,91.45384615384616,91.56307692307692,91.6723076923077,91.78153846153846,91.89076923076924,{"y":92,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":107.34,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.62,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.21,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.91,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97.39,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.2,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":108.88,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107.48,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":89.42,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97.54,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":91.7,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93.92,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.58,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$142.00

Average Price Target$124.58

Lowest Price Target$92.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Terence Flynn

Morgan Stanley

$115

Buy

28.74%

Upside

Assigned

08/10/26

Morgan Stanley Keeps Their Buy Rating on BioNTech SE (BNTX)

Jessica Fye

J.P. Morgan

$92

Hold

2.99%

Upside

Reiterated

08/06/26

J.P. Morgan Keeps Their Hold Rating on BioNTech SE (BNTX)

Unknown Analyst

Wells Fargo

Not Ranked

Wells Fargo

$140

Buy

56.72%

Upside

Reiterated

08/05/26

Wells Fargo Remains a Buy on BioNTech SE (BNTX)

Cory Kasimov

Evercore ISI

$135→$130

Buy

45.53%

Upside

Reiterated

08/05/26

BioNTech price target lowered to $130 from $135 at Evercore ISIBioNTech price target lowered to $130 from $135 at Evercore ISI

Geoff Meacham

Citi

$130→$125

Buy

39.93%

Upside

Reiterated

08/05/26

Analysts Offer Insights on Healthcare Companies: Pacira Pharmaceuticals (NASDAQ: PCRX), BioNTech SE (NASDAQ: BNTX) and Henry Schein (NASDAQ: HSIC)

Evan Seigerman

BMO Capital

$128

Buy

43.29%

Upside

Reiterated

08/05/26

BMO Capital Remains a Buy on BioNTech SE (BNTX)

Harry Gillis

Berenberg Bank

$140→$132

Buy

47.77%

Upside

Reiterated

08/05/26

Analysts Are Bullish on Top Healthcare Stocks: BioNTech SE (BNTX), Pfizer (PFE)

John Newman

Canaccord Genuity

$158→$142

Buy

58.96%

Upside

Assigned

08/05/26

BioNTech price target raised to $142 from $138 at CanaccordBioNTech price target raised to $142 from $138 at Canaccord

Akash Tewari

Jefferies

$138

Buy

54.48%

Upside

Reiterated

08/04/26

Jefferies Sticks to Their Buy Rating for BioNTech SE (BNTX)

Tazeen Ahmad

Bank of America Securities

$125→$122

Buy

36.57%

Upside

Reiterated

08/04/26

BioNTech: New Leadership and Advancing Oncology Pipeline Underpin Buy Rating Despite Lowered Price Target to $122

David Dai

UBS

$135

Buy

51.13%

Upside

Reiterated

08/04/26

BioNTech: Oncology Pipeline, Strong Leadership, and Cash Balance Support Buy Rating with Unchanged $135 Price Target

Jeffrey Walch

Bernstein

$96

Hold

7.47%

Upside

Reiterated

08/04/26

Bernstein Sticks to Their Hold Rating for BioNTech SE (BNTX)

Yaron Werber

TD Cowen

$94

Hold

5.23%

Upside

Reiterated

05/05/26

Analysts Offer Insights on Healthcare Companies: Orthofix Medical (NASDAQ: OFIX), BioNTech SE (NASDAQ: BNTX) and Cogent Biosciences (NASDAQ: COGT)

Asad Haider

Goldman Sachs

$132→$133

Buy

48.89%

Upside

Reiterated

05/05/26

BioNTech SE (BNTX) Receives a Buy from Goldman Sachs

Robert Burns

H.C. Wainwright

$130

Buy

45.53%

Upside

Reiterated

04/27/26

Analyst Reiterates Buy on BioNTech, Maintains $130 Price Target on Strength of Pumitamig Oncology Pipeline

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Terence Flynn

Morgan Stanley

$115

Buy

28.74%

Upside

Assigned

08/10/26

Morgan Stanley Keeps Their Buy Rating on BioNTech SE (BNTX)

Jessica Fye

J.P. Morgan

$92

Hold

2.99%

Upside

Reiterated

08/06/26

J.P. Morgan Keeps Their Hold Rating on BioNTech SE (BNTX)

Unknown Analyst

Wells Fargo

Not Ranked

Wells Fargo

$140

Buy

56.72%

Upside

Reiterated

08/05/26

Wells Fargo Remains a Buy on BioNTech SE (BNTX)

Cory Kasimov

Evercore ISI

$135→$130

Buy

45.53%

Upside

Reiterated

08/05/26

BioNTech price target lowered to $130 from $135 at Evercore ISIBioNTech price target lowered to $130 from $135 at Evercore ISI

Geoff Meacham

Citi

$130→$125

Buy

39.93%

Upside

Reiterated

08/05/26

Analysts Offer Insights on Healthcare Companies: Pacira Pharmaceuticals (NASDAQ: PCRX), BioNTech SE (NASDAQ: BNTX) and Henry Schein (NASDAQ: HSIC)

Evan Seigerman

BMO Capital

$128

Buy

43.29%

Upside

Reiterated

08/05/26

BMO Capital Remains a Buy on BioNTech SE (BNTX)

Harry Gillis

Berenberg Bank

$140→$132

Buy

47.77%

Upside

Reiterated

08/05/26

Analysts Are Bullish on Top Healthcare Stocks: BioNTech SE (BNTX), Pfizer (PFE)

John Newman

Canaccord Genuity

$158→$142

Buy

58.96%

Upside

Assigned

08/05/26

BioNTech price target raised to $142 from $138 at CanaccordBioNTech price target raised to $142 from $138 at Canaccord

Akash Tewari

Jefferies

$138

Buy

54.48%

Upside

Reiterated

08/04/26

Jefferies Sticks to Their Buy Rating for BioNTech SE (BNTX)

Tazeen Ahmad

Bank of America Securities

$125→$122

Buy

36.57%

Upside

Reiterated

08/04/26

BioNTech: New Leadership and Advancing Oncology Pipeline Underpin Buy Rating Despite Lowered Price Target to $122

David Dai

UBS

$135

Buy

51.13%

Upside

Reiterated

08/04/26

BioNTech: Oncology Pipeline, Strong Leadership, and Cash Balance Support Buy Rating with Unchanged $135 Price Target

Jeffrey Walch

Bernstein

$96

Hold

7.47%

Upside

Reiterated

08/04/26

Bernstein Sticks to Their Hold Rating for BioNTech SE (BNTX)

Yaron Werber

TD Cowen

$94

Hold

5.23%

Upside

Reiterated

05/05/26

Analysts Offer Insights on Healthcare Companies: Orthofix Medical (NASDAQ: OFIX), BioNTech SE (NASDAQ: BNTX) and Cogent Biosciences (NASDAQ: COGT)

Asad Haider

Goldman Sachs

$132→$133

Buy

48.89%

Upside

Reiterated

05/05/26

BioNTech SE (BNTX) Receives a Buy from Goldman Sachs

Robert Burns

H.C. Wainwright

$130

Buy

45.53%

Upside

Reiterated

04/27/26

Analyst Reiterates Buy on BioNTech, Maintains $130 Price Target on Strength of Pumitamig Oncology Pipeline

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

BTSGBrightSpring Health Services, Inc.

AMLXAmylyx Pharmaceuticals Inc

IMMXImmix Biopharma

TNYATenaya Therapeutics

JBIOJade Biosciences

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering BioNTech SE

3 Months

John NewmanCanaccord Genuity

Success Rate

10/14 ratings generated profit

Average Return

+5.29%

Copying John Newman's trades and holding each position for 3 Months would result in 71.43% of your transactions generating a profit, with an average return of +5.29% per trade.

1 Year

Robert BurnsH.C. Wainwright

Success Rate

12/24 ratings generated profit

Average Return

+1.41%

Copying Robert Burns's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +1.41% per trade.

2 Years

Robert BurnsH.C. Wainwright

Success Rate

11/24 ratings generated profit

Average Return

-3.53%

Copying Robert Burns's trades and holding each position for 2 Years would result in 45.83% of your transactions generating a profit, with an average return of -3.53% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BNTX Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, BNTX has received 17 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. BNTX average Analyst price target in the past 3 months is 124.58.

Each month's total comprises the sum of three months' worth of ratings.

BNTX Financial Forecast

BNTX Earnings Forecast

Next quarter’s earnings estimate for BNTX is $0.85 with a range of -$0.02 to $1.57. The previous quarter’s EPS was -$3.74. BNTX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year BNTX has Performed in-line its overall industry.

BNTX Sales Forecast

Next quarter’s sales forecast for BNTX is $1.22B with a range of $980.98M to $1.40B. The previous quarter’s sales results were $122.78M. BNTX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year BNTX has Performed in-line its overall industry.

BNTX Stock Forecast FAQ

What is BNTX’s average 12-month price target, according to analysts?

Based on analyst ratings, Biontech Se Sponsored Adr’s 12-month average price target is 124.58.

What is BNTX’s upside potential, based on the analysts’ average price target?

Biontech Se Sponsored Adr has 39.46% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is BNTX a Buy, Sell or Hold?

Biontech Se Sponsored Adr has a consensus rating of Strong Buy which is based on 10 buy ratings, 2 hold ratings and 0 sell ratings.

What is Biontech Se Sponsored Adr’s price target?

The average price target for Biontech Se Sponsored Adr is 124.58. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $142.00 ,the lowest forecast is $92.00. The average price target represents 39.46% Increase from the current price of $89.33.

What do analysts say about Biontech Se Sponsored Adr?

Biontech Se Sponsored Adr’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.

How can I buy shares of BNTX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

BioNTech SE (BNTX) Stock Forecast & Price Target

BNTX Analyst Ratings

BNTX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering BioNTech SE

BNTX Analyst Recommendation Trends

BNTX Financial Forecast

BNTX Earnings Forecast

BNTX Sales Forecast

BNTX Stock Forecast FAQ

Detailed List of Analyst Forecasts